Gene variations in oestrogen pathways, CYP19A1, daily 17β-estradiol and mammographic density phenotypes in premenopausal women

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Flote, Vidar G ^a   Furberg, Anne Sofie ^b   McTiernan, Anne ^c   Frydenberg, Hanne ^a   Ursin, Giske ^d   Iversen, Anita ^b   Lofteroed, Trygve ^a   Ellison, Peter T ^e   Wist, Erik A ^a   Egeland, Thore ^f   Wilsgaard, Tom ^b   Makar, Karen W ^c   Chang Claude, Jenny ^g   Thune, Inger ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c USA   (United States)

^d CANCER REGISTRY OF NORWAY   (Norway)

^e HARVARD UNIVERSITY   (United States)

^f NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; DNA; ESTRADIOL; ESTROGEN; CYP19A1 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; BODY MASS; BREAST CANCER; BREAST DENSITY; COMPUTER ANALYSIS; COMPUTER ASSISTED METHOD; DNA DETERMINATION; ESTRADIOL BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; LEAN BODY WEIGHT; LIFESTYLE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PHENOTYPE; PREMENOPAUSE; QUANTITATIVE ANALYSIS; SALIVA LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; CONGENITAL MALFORMATION; GENETICS; MAMMARY GLAND; METABOLISM;

ADULT; AROMATASE; BODY MASS INDEX; BREAST NEOPLASMS; ESTRADIOL; FEMALE; GENETIC VARIATION; HUMANS; MAMMARY GLANDS, HUMAN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREMENOPAUSE;

EID: 84924259704     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0499-2     Document Type: Article

References (63)

1. Folkerd E, Dowsett M: Sex hormones and breast cancer risk and prognosis. Breast 2013, 22:S38-S43. doi:10.1016/j.breast.2013.07.007.
2. Key T, Appleby P, Barnes I, Reeves G: Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94:606-616.
3. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V, Sieri S, Brinton LA, Dorgan JF, Dossus L, Dowsett M, Eliassen AH, Fortner RT, Hankinson SE, Helzlsouer KJ, Hoffman-Bolton J, Comstock GW, Kaaks R, Kahle LL, Muti P, Overvad K, Peeters PH, Riboli E, Rinaldi S, Rollison DE, Stanczyk FZ, Trichopoulos D, et al: Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 2013, 14:1009-1019. doi:10.1016/S1470-2045(13)70301-2.
4. Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, A'Hern R, Smith IE, Dowsett M: Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 2013, 138:157-165. doi:10.1007/s10549-013-2426-0.
5. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994, 15:342-355.
6. Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M: The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 2003, 86:219-224.
7. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, Dannenberg AJ: Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011, 4:1021-1029.
8. Zhao Y, Nichols JE, Valdez R, Mendelson CR, Simpson ER: Tumor necrosis factor-α stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol 1996, 10:1350-1357.
9. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P, Kopelovich L, Hudis CA, Dannenberg AJ: Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011, 4:329-346.
10. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burtt N, Calle EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Feigelson HS, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Le Marchand L, Lenner P, Lund E, et al: Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007, 67:1893-1897. doi:10.1158/0008-5472.can-06-4123.
11. Tamimi RM, Hankinson SE, Colditz GA, Byrne C: Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005, 14:2641-2647. doi:10.1158/1055-9965.epi-05-0558.
12. Becker S, Kaaks R: Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk? Recent Results Cancer Res 2009, 181:135-157.
13. Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A: Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat 2008, 108:57-67.
14. Walker K, Fletcher O, Johnson N, Coupland B, McCormack VA, Folkerd E, Gibson L, Hillier SG, Holly JM, Moss S, Dowsett M, Peto J, dos Santos Silva I: Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res 2009, 69:6490-6499.
15. Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA: The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 2005, 162:826-834. doi:10.1093/aje/kwi286.
16. McCormack VA, dos Santos SI: Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:1159-1169.
17. Pettersson A, Graff RE, Ursin G, dos Santos Silva I, McCormack V, Baglietto L, et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. in press. doi: 10.1093/jnci/dju078.
18. Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, Parisky YR, Hamilton AS, Astrahan MA, Mack T: The relative importance of genetics and environment on mammographic density. Cancer Epidemiol Biomarkers Prev 2009, 18:102-112.
19. Boyd NF, Martin LJ, Rommens JM, Paterson AD, Minkin S, Yaffe MJ, Stone J, Hopper JL: Mammographic density: a heritable risk factor for breast cancer. Methods Mol Biol 2009, 472:343-360. doi:10.1007/978-1-60327-492-0_15.
20. Lindström S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, Brown J, Leyland J, Audley T, Wareham NJ, Loos RJ, Paterson AD, Rommens J, Waggott D, Martin LJ, Scott CG, Pankratz VS, Hankinson SE, Hazra A, Hunter DJ, Hopper JL, Southey MC, Chanock SJ, dos Santos Silva I, Liu J, Eriksson L, Couch FJ, Stone J, Apicella C, Czene K, et al: Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet 2011, 43:185-187. doi:10.1038/ng.760.
21. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA: Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 2000, 11:653-662.
22. Ursin G, Longnecker MP, Haile RW, Greenland S: A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology 1995, 6:137-141.
23. Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, Shimazu T, Tsugane S, the Japan Public Health Center-based Prospective Study Group: Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status-the Japan public health center-based prospective study. Int J Cancer 2011, 129:1214-1224. doi:10.1002/ijc.25744.
24. Suzuki S, Kojima M, Tokudome S, Mori M, Sakauchi F, Wakai K, Fujino Y, Lin Y, Kikuchi S, Tamakoshi K, Tamakoshi A: Obesity/weight gain and breast cancer risk: findings from the Japan collaborative cohort study for the evaluation of cancer risk. J Epidemiol 2013, 23:139-145.
25. Michels KB, Terry KL, Eliassen AH, Hankinson SE, Willett WC: Adult weight change and incidence of premenopausal breast cancer. Int J Cancer 2012, 130:902-909. doi:10.1002/ijc.26069.
26. Harris HR, Willett WC, Terry KL, Michels KB: Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. J Natl Cancer Inst 2011, 103:273-278. doi:10.1093/jnci/djq500.
27. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjønneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quirós JR, Martínez C, et al: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004, 111:762-771. doi:10.1002/ijc.20315.
28. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A: Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer 2009, 124:698-712. doi:10.1002/ijc.23943.
29. Emaus A, Espetvedt S, Veierød MB, Ballard-Barbash R, Furberg AS, Ellison PT, Jasienska G, Hjartåker A, Thune I: 17-β-estradiol in relation to age at menarche and adult obesity in premenopausal women. Hum Reprod 2008, 23:919-927.
30. Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF, Ellison PT, Thune I: Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study. Cancer Epidemiol Biomarkers Prev 2005, 14:33-40.
31. Lillegaard IT, Andersen LF: Validation of a pre-coded food diary with energy expenditure, comparison of under-reporters v. acceptable reporters. Br J Nutr 2005, 94:998-1003.
32. Lipson SF, Ellison PT: Development of protocols for the application of salivary steroid analysis to field conditions. Am J Hum Biol 1989, 1:249-255. doi:10.1002/ajhb.1310010304.
33. Ellison PT, Lipson SF: Salivary estradiol-a viable alternative? Fertil Steril 1999, 72:951-952.
34. Lipson SF, Ellison PT: Comparison of salivary steroid profiles in naturally occurring conception and non-conception cycles. Hum Reprod 1996, 11:2090-2096.
35. Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV: The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998, 7:43-47.
36. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC: Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003, 12:332-338.
37. Passarelli MN, Phipps AI, Potter JD, Makar KW, Coghill AE, Wernli KJ, White E, Chan AT, Hutter CM, Peters U, Newcomb PA: Common single-nucleotide polymorphisms in the estrogen receptor β promoter are associated with colorectal cancer survival in postmenopausal women. Cancer Res 2013, 73:767-775. doi:10.1158/0008-5472.can-12-2484.
38. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA: Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004, 74:106-120. doi:10.1086/381000.
39. Thorisson GA, Smith AV, Krishnan L, Stein LD: The International HapMap Project Web site. Genome Res 2005, 15:1592-1593. doi:10.1101/gr.4413105.
40. Rice MS, Biessy C, Lajous M, Bertrand KA, Tamimi RM, Torres-Mejía G, López-Ridaura R, Romieu I: Metabolic syndrome and mammographic density in Mexican women. Cancer Prev Res (Phila) 2013, 6:701-710. doi:10.1158/1940-6207.CAPR-12-0475.
41. Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Pita G, Alonso MR, Dennis J, Wang Q, Bolla MK, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Ko YD, Brauch H, Hamann U, Network GENICA, Andrulis IL, Knight JA, Glendon G, Tchatchou S, kConFab Investigators, Australian Ovarian Cancer Study Group, Matsuo K, Ito H, et al: Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2014, 23:6096-6111. doi:10.1093/hmg/ddu311.
42. Robbez-Masson LJ, Bödör C, Jones JL, Hurst HC, Fitzgibbon J, Hart IR, Grose RP: Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing. PLoS One 2013, 8:e78839. doi:10.1371/journal.pone.0078839.
43. Cai H, Shu XO, Egan KM, Cai Q, Long JR, Gao YT, Zheng W: Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women. Pharmacogenet Genomics 2008, 18:657-664. doi:10.1097/FPC.0b013e3282fe3326.
44. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN: Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010, 70:319-328. doi:10.1158/0008-5472.can-09-3224.
45. Li J, Eriksson L, Humphreys K, Czene K, Liu J, Tamimi RM, Lindström S, Hunter DJ, Vachon CM, Couch FJ, Scott CG, Lagiou P, Hall P: Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer. Breast Cancer Res 2010, 12:R19. doi:10.1186/bcr2488.
46. Ozhand A, Lee E, Wu AH, Ellingjord-Dale M, Akslen LA, McKean-Cowdin R, Ursin G: Variation in inflammatory cytokine/growth-factor genes and mammographic density in premenopausal women aged 50-55. PLoS One 2013, 8:e65313.
47. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Børresen-Dale AL: A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998, 8:43-48.
48. Low YL, Li Y, Humphreys K, Thalamuthu A, Li Y, Darabi H, Wedrén S, Bonnard C, Czene K, Iles MM, Heikkinen T, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Liu ET, Liu J: Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. PLoS Genet 2010, 6:e1001012. doi:10.1371/journal.pgen.1001012.
49. Ma X, Qi X, Chen C, Lin H, Xiong H, Li Y, Jiang J: Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls. Breast Cancer Res Treat 2010, 122:495-501.
50. Talbott KE, Gammon MD, Kibriya MG, Chen Y, Teitelbaum SL, Long CM, Gurvich I, Santella RM, Ahsan H: A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat 2008, 111:481-487. doi:10.1007/s10549-007-9794-2.
51. Zins K, Mogg M, Schneeberger C, Abraham D, Schreiber M: Analysis of the rs10046 Polymorphism of Aromatase (CYP19) in Premenopausal Onset of Human Breast Cancer. Int J Mol Sci 2014, 15:712-724. doi:10.3390/ijms15010712.
52. Liedtke S, Schmidt ME, Vrieling A, Lukanova A, Becker S, Kaaks R, Zaineddin AK, Buck K, Benner A, Chang-Claude J, Steindorf K: Postmenopausal sex hormones in relation to body fat distribution. Obesity (Silver Spring) 2012, 20:1088-1095. doi:10.1038/oby.2011.383.
53. Williams NI, Reed JL, Leidy HJ, Legro RS, De Souza MJ: Estrogen and progesterone exposure is reduced in response to energy deficiency in women aged 25-40 years. Hum Reprod 2010, 25:2328-2339. doi:10.1093/humrep/deq172.
54. Campbell KL, Foster-Schubert KE, Alfano CM, Wang CC, Wang CY, Duggan CR, Mason C, Imayama I, Kong A, Xiao L, Bain CE, Blackburn GL, Stanczyk FZ, McTiernan A: Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J Clin Oncol 2012, 30:2314-2326.
55. Iversen A, Thune I, McTiernan A, Makar KW, Wilsgaard T, Ellison PT, Jasienska G, Flote V, Poole EM, Furberg AS: Genetic polymorphism CYP17 rs2486758 and metabolic risk factors predict daily salivary 17β-estradiol concentration in healthy premenopausal Norwegian women. The EBBA-I study. J Clin Endocrinol Metab 2012, 97:E852-E857.
56. Yaghjyan L, Colditz GA, Rosner B, Tamimi RM: Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to the time since the mammogram. Cancer Epidemiol Biomarkers Prev 2013, 22:1110-1117.
57. van Gils CH, Hendriks JH, Otten JD, Holland R, Verbeek AL: Parity and mammographic breast density in relation to breast cancer risk: indication of interaction. Eur J Cancer Prev 2000, 9:105-111.
58. Lin JH, Gunter MJ, Manson JE, Rexrode KM, Cook NR, Kraft P, Cochrane BB, Chlebowski RT, Ho GY, Zhang SM: The aromatase gene ( CYP19A1 ) variants and circulating hepatocyte growth factor in postmenopausal women. PLoS One 2012, 7:e42079. doi:10.1371/journal.pone.0042079.
59. Casbas-Hernandez P, D'Arcy M, Roman-Perez E, Brauer HA, McNaughton K, Miller SM, Chhetri RK, Oldenburg AL, Fleming JM, Amos KD, Makowski L, Troester MA: Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res 2013, 15:R82. doi:10.1186/bcr3476.
60. Schoemaker MJ, Folkerd EJ, Jones ME, Rae M, Allen S, Ashworth A, Dowsett M, Swerdlow AJ: Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study. Br J Cancer 2014, 110:1898-1907. doi:10.1038/bjc.2014.64.
61. Tworoger SS, Zhang X, Eliassen AH, Qian J, Colditz GA, Willett WC, Rosner BA, Kraft P, Hankinson SE: Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol 2014, 32:3111-3117. doi:10.1200/jco.2014.56.1068.
62. Holst JP, Soldin OP, Guo T, Soldin SJ: Steroid hormones: relevance and measurement in the clinical laboratory. Clin Lab Med 2004, 24:105-118. doi:10.1016/j.cll.2004.01.004.
63. Furberg AS, Veierød MB, Wilsgaard T, Bernstein L, Thune I: Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004, 96:1152-1160.